Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spiked “Supplements” For Diabetes, Pain On The Rise

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is seeing supplements spiked with prescription ingredients indicated for pain management and diabetes treatment and needs industry help identifying violators, Center for Food Safety and Applied Nutrition head Michael Landa says.

You may also be interested in...

In Brief

Hi-Tech OTC sales fall; social media posts prompt FDA warning; FDA warns PruTect Rx about claims; study finds no DMAA in geranium oil; prebiotic recall spreads to Eco Health product; more news In Brief.

Regulatory News In Brief

FDA warns Healing Ways to register facility; Dragon Herbs warned for tradeshow materials; BNE recalls ephedra-spiked supplements; supplement flu prevention claims cross the line; more regulatory news in brief.

FDA Expects STD Claims Enforcement To Deter Future Violations

FDA will consider prosecuting executives of firms making unapproved sexually transmitted disease treatment claims for OTC drugs and nutritional products, the targets of its latest enforcement sweep.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts